Aldeyra Therapeutics Newsroom

After Losing 47% in the Past Year, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Institutional Owners Must Be Relieved by the Recent Gain

Simply Wall StJul 17 10:22 ET

BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $11

moomoo NewsJun 17 06:33 ET · Ratings

Express News | Aldeyra Therapeutics Inc: Clinical Trial Results and Potential New Drug Application Resubmission Expected in Second Half of 2024

ReutersJun 13 07:00 ET

Express News | Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

ReutersJun 13 07:00 ET

Aldeyra Therapeutics to Host Investor Roundtable QA

Aldeyra TherapeuticsJun 12 00:00 ET

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

Aldeyra TherapeuticsMay 29 00:00 ET

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)

TipRanksMay 24 01:51 ET

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

Yahoo FinanceMay 14 09:40 ET

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study

MT NewswiresMay 8 15:12 ET

Express News | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease, Clinical Results and Potential New Drug Application Submission Expected In 2H Of 2024

BenzingaMay 8 07:14 ET

Express News | Aldeyra Therapeutics Inc - Clinical Results and Potential New Drug Application Submission Expected in Second Half of 2024

ReutersMay 8 07:00 ET

Express News | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

ReutersMay 8 07:00 ET

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer

Dow JonesMay 6 07:57 ET

Oppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)

TipRanksMay 6 07:47 ET

Express News | HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

BenzingaMay 6 06:38 ET

Analysts Offer Insights on Healthcare Companies: Owens & Minor (OMI), Vertex Pharmaceuticals (VRTX) and Aldeyra Therapeutics (ALDX)

TipRanksMay 6 06:20 ET

Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)

TipRanksApr 30 03:31 ET

Aldeyra Therapeutics Unveils R&D Progress and Goals

TipRanksApr 25 07:13 ET

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

BusinesswireApr 25 07:00 ET

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Aldeyra TherapeuticsApr 18 00:00 ET